A report of improved sleep after Epitalon does not establish a permanent reset. Duration of benefit is a separate clinical question from whether a change was noticed during or shortly after exposure.
The outcome must first be demonstrated
The FDA's clinical assessment found that the cited human biomarker work did not measure insomnia outcomes. A study that does not establish improved sleep cannot establish how long an insomnia benefit lasts after treatment.
The word reset suggests a durable correction of an underlying process. That claim requires evidence of the process, the clinical outcome and persistence, not just a persuasive explanation involving the pineal gland.
Follow-up needs more than a favorable recollection
A useful durability study would define the treatment period and follow-up, measure sleep consistently and account for other care and schedule changes. It would include people who did not improve or stopped participating, not only those who posted positive experiences.
Season, work patterns, stress, illness and other treatment can also change across a person's observation period. Recognizing those possibilities does not dismiss their experience; it limits the certainty of the explanation.
A later return of sleep difficulty similarly does not prove a need for another Epitalon course.
Bring the pattern back to clinical assessment
The NHLBI diagnosis page describes how a sleep diary can help make patterns visible. Record symptoms and daily impact for a clinician without using that record as a reason to continue an experimental exposure.
If a prescribed treatment is involved, do not stop or alter it to test an internet reset theory. Discuss the goal and follow-up plan with the treating professional.
The sources cited here do not establish a permanent sleep correction, a maintenance interval or a restart rule for Epitalon. A short anecdote cannot establish a long-term treatment promise.